IP Library Granted Patent US 6,984,667
Granted Patent B2
US 6,984,667 · App. 09/771,669 · Granted Jan 10, 2006

Synergistic proteoglycan compositions for inflammatory conditions

Assignee: Theta Biomedical Consulting and Development Co.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,984,667
App. No.
09/771,669
Granted
Jan 10, 2006
Kind
B2
Abstract

Compositions with synergistic anti-inflammatory effect in inflammatory diseases resulting from activation and consequent degranulation of mast cell and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as chondroitin sulfate C and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, a special organic extra virgin kernel seed olive oil, S-adenosylmethionine and diphenhydramine.

Claims (27)

1. A composition with synergistic anti-inflammatory properties for use in conditions induced by inflammatory disease-causing biomolecules released from mast cells by the activation and degranulation of said mast cells, comprising a non-bovine proteoglycan and unrefined kernel olive oil, and one or more of D-hexosamine sulfate, a flavonoid, S-adenosyimethionine, and a histamine-1-receptor antagonist, in an appropriate excipient or vehicle for oral or topical administration.

2. The composition according to claim 1 , wherein said sulfated proteoglycan is selected from the group consisting of non-bovine chondroitin sulfate, keratan sulfate, dermatan sulfate and hyaluronic acid.

3. The composition according to claim 2 , wherein said chondroitin sulfate is derived from shark cartilage.

4. The composition according to claim 1 , wherein said hexosamine sulfate is D-glucosamine sulfate.

5. The composition according to claim 1 , wherein said flavone is selected from the group consisting of quercetin, myrisetin, genistein and kaempferol.

6. The composition according to claim 1 , wherein said olive oil contains omega fatty acids and alpha-tocopherol.

7. The composition according to claim 1 , said composition being for oral use, comprising 300 mg each of non-bovine chondroitin sulfate C, quercetin and D-glucosamine sulfate, in kernel olive oil.

8. The composition according to claim 7 , further comprising 100 mg of S-adenosylmethionine.

9. The composition according to claim 1 , wherein said inflammatory disease is arthritis and said composition is contained in an ointment or cream for topical application, comprising, in mg %, chondroitin sulfate 0.05; unrefined kernel olive oil, 1-5; and one or more of D-glucosamine sulfate, 0.05, and quercetin, 0.03.

10. The composition according to claim 9 , further comprising diphenhydramine, 5 mg %.

11. A composition according to claim 1 , said composition consisting of a mouth wash composition, comprising chondroitin sulfate, 0.4 M; unrefined kernel olive oil 0.5-1.5 mg %; and one or more of D-glucosamine sulfate, 0.4 M; and quercetin, 0.3 M, in a mouth wash vehicle.

12. A composition according to claim 1 , said composition consisting of a tooth paste, comprising, in mg %, chondroitin sulfate, 0.05; and unrefined kernel olive oil, 1-5, and one or more of D-glucosamine sulfate, 0.05; and quercetin, 0.03; in a tooth paste vehicle.

13. A composition according to claim 1 , said composition consisting of a sunscreen composition, comprising, in mg %, chondroitin sulfate, 0.05, and unrefined kernel oil, 1-5; and one or more of D-glucosamine sulfate, 0.05; quercetin, 0.03; and titanium dioxide, 1-5; in a sun screen vehicle.

14. A method of treating a subject suffering from am inflammatory disease, wherein said inflammatory disease results from biomolecules secreted from activated and degranulated mast cells, said inflammatory disease being selected from the group consisting of osteoarthritis, cancer, fibromyalgia, atherosclerosis, inflammatory bowel disease, interstitial cystitis, irritable bowel syndrome, migraines, angina, chronic prostatitis, eczema, arthritis, multiple sclerosis, psoriasis, sun burn, and periodontal disease, comprising the step of administering to said subject an effective amount of a composition according to claim 1 .

15. The composition according to claim 1 , wherein said histamine-1-receptor antagonist is diphenhydramine.

16. The composition according to claim 1 , wherein said inflammatory disease is arthritis and said composition is designed for oral administration, comprising non-bovine chondroitin sulfate, quercetin, D-glucosamine sulfate, and unrefined kernel olive oil.

17. The composition according to claim 9 , comprising, in mg %, chondroitin sulfate, 0.05; D-glucosamine sulfate, 0.05; quercetin, 0.03; and, unrefined kernel olive oil, 1-5.

18. The composition according to claim 1 for oral use in allergic conditions, comprising chondroitin sulfate, a flavonoid selected from the group consisting of quercetin, myricetin and kaempferol, and said kernel olive oil.

19. The composition according to claim 18 , comprising 200 mg each of chondroitin sulfate and kaempferol and said kernel olive oil.

20. The composition according to claim 18 , comprising chondroitin sulfate and myricetin and said kernel olive oil.

21. The composition according to claim 20 , supplemented with a histamine-1-receptor antagonist.

22. The composition according to claim 21 , wherein said antagonist is diphenhydramine.

23. The composition according to claim 1 , wherein said inflammatory disease is cancer and wherein said composition is designed for oral use, comprising 25-50 mg of genistein and 150-300 mg of quercetin, and said kernel olive oil.

24. The composition according to claim 1 , wherein said inflammatory disease is atherosclerosis with or without myocardial ischemia, comprising 100-300 mg each of chondroitin sulfate, myricetin and S-adenosylmethionine, and said kernel olive oil, in a vehicle for oral use.

25. The composition according to claim 1 , wherein said inflammatory disease is interstitial cystitis, said composition comprising 100-300 mg of chondroitin sulfate, 100-300 mg of hyaluronic acid, and 200-400 mg quercetin, and said kernel olive oil, in a vehicle for oral use.

26. The composition according to claim 1 , wherein said inflammatory disease is prostatitis, said composition comprising 100-200 mg of chondroitin sulfate, 100-200 mg hyaluronic acid and 200-400 mg of quercetin, and said kernel olive oil, in a vehicle for oral use.

27. The composition according to claim 1 , wherein said inflammatory disease is multiple sclerosis, said composition comprising 100-300 mg each of chondroitin sulfate, myricetin and S-adenosylmethionine, and said kernel olive oil, in a vehicle for oral use.

Assignments (2)
MERGER Recorded Apr 12, 2022
From: THETA BIOMEDICAL CONSULTING AND DEVELOPMENT CO., INC.
To: THETA BIOMEDICAL CONSULTING AND DEVELOPMENT, LLC
Reel/Frame 060005/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2001
From: THEOHARIS, THEOHARIS C.
To: THETA BIOMEDICAL CONSULTING AND DEVELOPMENT CO.
Reel/Frame 012063/0972 →
Continuity (2)
Continuation In Part 0905670700 · Apr 8, 1998
Related Publication 20020176902A1 · Nov 28, 2002